Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Cardiovasc Ther ; 2024: 4405152, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38505191

RESUMEN

Insufficient data exist regarding the investigation of the impact of novel oral anticoagulants (NOACs) on coagulation activation biomarkers in the context of left atrial appendage closure (LAAC) and device-related thrombosis (DRT). The study was designed to investigate the changes and presence of coagulation activation biomarkers between different antithrombotic strategies following LAAC. A total of 120 nonvalvular atrial fibrillation patients intolerant of long-term anticoagulants, who underwent successful WATCHMAN closure implantation, were enrolled (rivaroxaban, n = 82; dabigatran, n = 38). Blood samples were obtained from left atrium (LA) and left atrial appendage (LAA) during the operation and fasting blood samples on the same day of LAAC and 45 days after discharge. The biochemical indicators, thrombin-antithrombin complex (TAT), soluble P-selectin (sP-selectin), von Willebrand factor (vWF), and CD40 ligand (CD40L), were measured by enzyme-linked immunosorbent assay. The primary endpoints of this study were the efficacy and safety characteristics of different antithrombotic strategies, including DRT incidence, stroke or transient ischemic attack, systemic embolism, and clinical major and nonmajor bleeding complications during the follow-up of 180 days. The results revealed that TAT, vWF, sP-selectin, and CD40L levels in vein were significantly reduced by 2.4% (p = 0.043), 5.0% (p < 0.001), 8.7% (p < 0.001), and 2.5% (p = 0.043) from their baseline levels after rivaroxaban treatment. Conversely, no significant changes were detected in the dabigatran group. Furthermore, the plasma levels of platelet activation biomarkers (CD40L and sP-selectin) in both LA and LAA groups were significantly lower after anticoagulation with rivaroxaban, as compared to dabigatran treatment (CD40L: 554.62 ± 155.54 vs. 445.02 ± 130.04 for LA p = 0.0013, 578.51 ± 156.28 vs. 480.13 ± 164.37 for LAA p = 0.0052; sP-selectin: 2849.07 ± 846.69 vs. 2225.54 ± 799.96 for LA p = 0.0105, 2915.52 ± 1402.40 vs. 2203.41 ± 1061.67 for LAA p = 0.0022). Notably, the present study suggests that rivaroxaban may be more effective in the prevention of DRT for patients undergoing LAAC.


Asunto(s)
Apéndice Atrial , Fibrilación Atrial , Accidente Cerebrovascular , Trombosis , Humanos , Rivaroxabán/efectos adversos , Anticoagulantes/efectos adversos , Dabigatrán/efectos adversos , Cierre del Apéndice Auricular Izquierdo , Administración Oral , Factor de von Willebrand/farmacología , Factor de von Willebrand/uso terapéutico , Fibrinolíticos/uso terapéutico , Ligando de CD40/farmacología , Ligando de CD40/uso terapéutico , Resultado del Tratamiento , Accidente Cerebrovascular/prevención & control , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/complicaciones , Activación Plaquetaria , Biomarcadores , Selectinas/farmacología , Selectinas/uso terapéutico
2.
Hum Antibodies ; 18(1-2): 41-3, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19478398

RESUMEN

Peripheral blood lymphocytes (PBL) from a patient allergic to Japanese cedar pollens, were stimulated with IL-4, IL-13, CD40-Ligand and/or hydrocortisone in the presence of Epstein-Barr virus in 96-well round bottomed culture plates, and the secretion of IgE-class antibody against a Japanese cedar pollen allergen Cry j1 in the supernatants were examined. PBL cultured with IL-4, and IL-4 + CD40-Ligand showed the highest IgE secretion and the cultures were maintained for 30 days. However, we failed to expand the culture with high IgE secretion. It was suggested that patient's PBL stimulated with IL-4 were useful for short term IgE production to Cry j1.


Asunto(s)
Alérgenos/inmunología , Inmunoglobulina E/biosíntesis , Linfocitos/inmunología , Proteínas de Plantas/inmunología , Polen/inmunología , Antígenos de Plantas , Ligando de CD40/farmacología , Células Cultivadas , Cryptomeria/inmunología , Herpesvirus Humano 4 , Humanos , Hidrocortisona/farmacología , Interleucina-13/farmacología , Interleucina-4/farmacología , Linfocitos/efectos de los fármacos , Proteínas Recombinantes/farmacología , Rinitis Alérgica Estacional/inmunología
3.
J Immunol ; 175(1): 501-8, 2005 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-15972685

RESUMEN

Maturation of dendritic cells (DCs) induced by pathogen-derived signals via TLRs is a crucial step in the initiation of an adaptive immune response and therefore has to be well controlled. In this study, we demonstrate that oxidized phospholipids (ox-PLs), which are generated during infections, apoptosis, and tissue damage, interfere with DC activation, preventing their maturation. ox-PLs blocked TLR-3- and TLR-4-mediated induction of the costimulatory molecules CD40, CD80, CD83, and CD86, the cytokines IL-12 and TNF, as well as lymphocyte stimulatory capacity. CD40 and TLR-2-mediated cytokine production was also inhibited, whereas up-regulation of costimulatory molecules via these receptors was not affected by ox-PLs. Thus, formation of ox-PLs during the course of an inflammatory response may represent a negative-feedback loop preventing excessive and sustained immune reactions through regulating DC maturation.


Asunto(s)
Antígenos CD40/metabolismo , Células Dendríticas/citología , Células Dendríticas/inmunología , Glicoproteínas de Membrana/metabolismo , Fosfolípidos/inmunología , Fosfolípidos/metabolismo , Receptores de Superficie Celular/metabolismo , Secuencia de Bases , Ligando de CD40/farmacología , Diferenciación Celular , Citocinas/biosíntesis , ADN Complementario/genética , Células Dendríticas/efectos de los fármacos , Células Dendríticas/metabolismo , Retroalimentación , Humanos , Técnicas In Vitro , Inflamación/inmunología , Inflamación/metabolismo , Lipopolisacáridos/farmacología , Activación de Linfocitos/efectos de los fármacos , FN-kappa B/metabolismo , Oxidación-Reducción , Peptidoglicano/farmacología , Fosfatidilcolinas/farmacología , Fosfolípidos/química , Poli I-C/farmacología , Transducción de Señal/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Receptor Toll-Like 2 , Receptor Toll-Like 3 , Receptor Toll-Like 4 , Receptores Toll-Like
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA